Home › NCT06195241

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Benign essential blepharospasm (BEB) or hemifacial spasm (HFS) as diagnosed by an ophthalmologist.
* No known neurologic or neuromuscular systematic medications.
* No history or surgical intervention for BEB or HFS.
* Patients are required to have a minimum score of 4 out of 8 on the modified Jankovic Rating Scale for Severity/Frequency.

Exclusion Criteria:

* Patients will be excluded if age \< 18, are pregnant, are non-willing, or have contra-indications to botulinum toxin.

About the study

The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:

1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify? 2. What percentage of patients achieve a clinical response?

Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.

What is being tested

• DaxibotulinumtoxinA (drug)

Sponsor: Montefiore Medical Center · Participants: 40 · Started: Feb 11, 2025

Contact the study team

• Isaac M Weber, BA · Phone: 347-706-0146

Official record on ClinicalTrials.gov — NCT06195241

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.